Skip to content

Flatiron Health UK’s Research Oversight Process

What is the purpose of the Research Oversight Process?

The Research Oversight Process has been established to govern access to Flatiron Health UK’s Real-World Data (RWD) products. It will serve two key purposes:

Provide robust scientific, methodological and statistical oversight of the use and analysis of Flatiron Health UK RWD products through an internal Flatiron review process led by Flatiron’s clinical and data science teams.

Maintain trust and transparency of Flatiron Health UK RWD product use by academic researchers and commercial partners (i.e. life sciences companies) through an objective review conducted by a Research Transparency Panel. This panel will consist of independent clinicians, patients and lay representatives from across the UK.

This process has been approved by the NHS Health Research Authority.
If you are interested in accessing our UK data models, please contact us on: uk-dataaccess@flatiron.com 

What does the process entail?

Research oversight process
research oversight mobile

Note: Health insurers or cigarette manufacturers (as examples) would never be provided with access to the Flatiron Health UK RWD products (as described in our patient privacy notice), so should such requests be received, they would not be accepted through this process. 

Documentation

Data Access Register

For transparency, this tracker captures details of projects that have been approved by the Flatiron Health UK Data Access Register:

Organisation

Target diseases

Intended use case(s)

Date of request approval

Roche

  • Multiple myeloma

  • Diffuse large B-cell lymphoma

  • Chronic lymphatic leukemia

  • Prostate cancer

  • Breast cancer

  • Non-small cell lung cancer

  • Clinical trial design and feasibility

  • Health technology assessment, health economics outcomes research, and Market access

  • Understanding and monitoring the treatment landscape

30th November, 2023

Pfizer

  • Breast cancer 

  • Product development and portfolio strategy

  • Clinical trial design and feasibility

  • Supporting regulatory submissions

  • Product launch planning

  • Health technology assessment, health economics outcomes research, and Market access

  • Label / indication expansion

  • Understanding and monitoring the treatment landscape

14th December, 2023

Definitions of each of the use cases, can be found following this link.

Panel Summaries

Flatiron Health UK will also regularly publish summaries from panel meetings and summarise the outputs of asynchronous reviews. Through this process, Flatiron Health UK will also document and disclose details of unsuccessful applications to access Flatiron Health UK RWD products.

Annual Reports

Flatiron Health UK remains committed to summarising the meeting outputs in an annual research transparency report (written for the lay audience) that will document and describe such use cases (approved and rejected) and the impact of the research.  

Note: The Data Access Annual Report for 2023 will be disclosed here following the end of year review.